United-Guardian, Inc. — FY 2014 Form 10-K
Reporting period: Fiscal year ended December 31, 2014; comparisons are with the year ended December 31, 2013. This is an annual filing, not a standalone fourth-quarter report. United-Guardian manufactures and markets cosmetic and personal-care ingredients, pharmaceuticals, medical lubricants, and specialty industrial products. It reports one business segment. LUBRAJEL products generated about 85.9% of 2014 revenue; RENACIDIN generated about 8.8%.
Financial results and position
| Metric | 2014 | 2013 | Change |
|---|---|---|---|
| Net sales | $13.45 million | $15.42 million | Down 12.8% |
| Gross profit | $8.13 million | $9.81 million | Down about 17.1% |
| Cost of sales / net sales | 39.5% | 36.4% | Up 3.1 percentage points |
| Income from operations | $5.49 million | $7.30 million | Down about 24.8% |
| Net income | $4.05 million | $5.90 million | Down about 31.4% |
| Basic and diluted EPS | $0.88 | $1.28 | Down $0.40 |
| Net cash provided by operating activities | $4.48 million | $5.81 million | Down about 22.8% |
Calculated margins: gross margin was approximately 60.5% in 2014 versus 63.6% in 2013; operating margin was approximately 40.8% versus 47.4%; net margin was approximately 30.1% versus 38.3%. Other income fell to $264,000 from $1.33 million, principally because RENACIDIN supplier settlement payments largely ended. The settlement contributed $24,403 in 2014 versus $1.07 million in 2013.
At year-end, cash and cash equivalents were $2.02 million and marketable securities were $9.39 million. Working capital was $13.69 million, up 4.8%, and the current ratio was 15.0:1, compared with 11.5:1. Current liabilities were $975,000; the filing reports no debt or need for a credit line. Total assets were $15.94 million and stockholders’ equity was $14.74 million. The company said working capital was sufficient for the next fiscal year and reported no material future capital-expenditure commitments.
Operating cash flow was $4.48 million. Investing activities used $414,000, mainly reflecting marketable-security purchases net of sales; financing activities used $3.68 million, all dividends. Cash increased by $389,000. Dividends paid totaled $3.68 million in 2014, versus $4.46 million in 2013. R&D expense was approximately $730,000, compared with $717,000.
Material changes and management commentary
- Personal-care sales declined $2.04 million, or 17.8%, principally because sales to the largest marketing partner, Ashland Specialty Ingredients (ASI), fell 18.1%. Factors included a major ASI customer shifting part of its purchases to a second supplier and the timing of unusually large China-related orders placed late in 2013 and early 2014. ASI reported substantial new China-related orders in late 2014 and early 2015; management expected some lost customer business to return, but anticipated near-term sales to that customer would remain below prior levels.
- Total LUBRAJEL sales declined 18.1%, with unit volume down approximately 17.9%. The filing attributes the higher cost-of-sales ratio largely to lower production volumes and fixed overhead, along with product mix and customer discounts.
- Pharmaceutical sales rose 83.9%, mainly as RENACIDIN returned to availability after supplier production problems. RENACIDIN sales were $1.18 million, up from $452,000, but remained below historical levels. CLORPACTIN sales increased 8.5%.
- Non-pharmaceutical medical sales fell 17.6%, primarily after a customer discontinued a product ingredient; the discontinuation of LUBRAJEL LC sales to a customer also weighed on results. Industrial and other sales increased 3.3%.
- Foreign customers represented approximately 65% of sales, down from 70%. Two distributors/marketing partners accounted for 64.7% of revenue, and two accounted for 56.3% of year-end receivables. Sales are denominated in U.S. dollars, so management reported no foreign-exchange exposure from its sales.
Outlook, risks, contingencies, and unusual items
- RENACIDIN supply and FDA approval: The company extended its existing supply arrangement into the first quarter of 2015 and identified a replacement supplier. It applied to the FDA in August 2014 for approval of a new 30 mL single-dose container, targeting approval by the end of the first quarter of 2015 and launch in the third quarter. These were expectations, not guarantees; FDA delays could alter the timetable. The company planned to maintain inventory of the existing 500 mL bottle while awaiting approval.
- Business concentration and competition: LUBRAJEL and RENACIDIN together represented 94.6% of revenue. Reliance on ASI and other distributors, competition (including products from China), customer purchasing patterns, and economic weakness in Europe could affect sales. Some foreign distributor arrangements can be terminated at any time; the ASI agreement was extended through December 31, 2015.
- Operational dependencies: Five major raw-material vendors represented approximately 84% of raw-material purchases, versus 67% in 2013. The company also identifies customer concentration and potential inventory write-downs if demand or ordering patterns change.
- Pricing and margins: Customer discounts were $119,965 in 2014 versus $11,000 in 2013; $96,000 was accrued at year-end as rebates. Management anticipated lower rebates in 2015, partly because it expected to use price reductions instead.
- Development: The company hoped to sample a natural LUBRAJEL OIL formulation in 2015 and was discussing a second phase of development for a water-based condom lubricant. Management cautioned that development projects may not become marketable or commercially successful; R&D spending in 2015 was expected to be comparable to 2014.
- Other disclosures: The company reported no legal proceedings and no off-balance-sheet arrangements. It reported no material environmental-law impact; compliance costs were $42,000 in 2014. The financial statements received an unqualified audit opinion. Management concluded disclosure controls and internal control over financial reporting were effective; the auditor did not provide an internal-control attestation.
Important facts for investors to verify
- Whether FDA approval and the planned launch of RENACIDIN in the new single-dose container occurred, and whether the replacement supplier provides dependable supply.
- Whether RENACIDIN sales recover and whether reported sales to ASI and its customers—particularly the large customer using a second supplier and customers in China—develop as management expected.
- Whether personal-care volume, customer discounts, product mix, and fixed-cost absorption improve after the 2014 decline.
- How distributor and customer concentration, raw-material vendor concentration, and termination rights under marketing arrangements evolve.
- Whether operating cash generation and liquidity remain strong while the company funds dividends and product development.